ATRN-119

DRUG3 trials

Sponsors

Aprea Therapeutics, Abramson Cancer Center at Penn Medicine, Washington University School of Medicine

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorHPV (Human Papillomavirus)-Associated CarcinomaHPV Associated CancersHPV Positive Oropharyngeal Squamous Cell CarcinomaHigh-risk Myelodysplastic SyndromeOropharyngeal HPV Squamous Cell CarcinomaSquamous Cell Carcinoma

Phase 1

Study Of ATRN-119 In Patients With Advanced Solid Tumors

CompletedNCT04905914

Aprea TherapeuticsAdvanced Solid Tumor

Start: 2023-01-09End: 2026-03-09Updated: 2026-08-04

Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

Not yet recruitingNCT07578467

Abramson Cancer Center at Penn MedicineHPV Associated Cancers, HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma +2

Start: 2026-08-31End: 2030-08-31Target: 35Updated: 2026-07-08

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Not yet recruitingNCT07617363

Washington University School of MedicineAcute Myeloid Leukemia, High-risk Myelodysplastic Syndrome

Start: 2026-08-31End: 2031-12-31Target: 27Updated: 2026-06-01

Related Papers

Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors

Cancer Research2024-04-053 citations

Abstract C034: First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors

Molecular Cancer Therapeutics2023-12-01

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.

2021-12-1569 citations